A trial looking at women whose cervical cancer has come back after treatment (Scotcerv)

Cancer type:

Cervical cancer

Status:

Results

Phase:

Phase 2

This trial looked at gemcitabine and docetaxel (Taxotere) for women whose cervical cancer had come back after treatment.

Doctors usually treat cervical cancer with surgery and radiotherapy, and sometimes chemotherapy. But sometimes these treatments don’t work very well and the cancer starts to grow again (recurs).

Most women who have chemotherapy for cervical cancer have cisplatin. If the cancer starts to grow again, you can have a second course of cisplatin. But the second course often doesn’t work as well as the first.

Doctors thought the combination of gemcitabine and docetaxel might help women in this situation. But they were not sure how well it would work.

The aim of this trial was to see how well gemcitabine and docetaxel worked for cervical cancer that had come back after cisplatin chemotherapy. And to find out more about the side effects of this combination.

Summary of results

The trial team found that gemcitabine and docetaxel had similar results as other chemotherapy treatments for women whose cervical cancer had come back.

This trial recruited 50 women. The researchers split these women into 2 groups.

In group 1, there were 21 women. Their cancer had come back in the area between their hip bones (pelvis) only.

In group 2, there were 29 women. Their cancer had come back in other parts of the body, outside of their pelvis.

Everyone had docetaxel and gemcitabine.

Of the women in group 1

  • In 2 women, the cancer got smaller – doctors call this a partial response
  • In 6 women, the cancer stayed the same – doctors call this stable disease
  • In 4 women, their cancer continued to grow
  • In the remaining 9 women the researchers couldn’t examine their cancer again because their health had got worse

Of the women in group 2

  • In 6 women there was a partial response
  • In 7 women there was stable disease
  • In 9 women the cancer continued to grow
  • Unfortunately 1 woman died before treatment started
  • In the remaining 6 women the researchers couldn’t examine their cancer again because their health had got worse

The most common side effect was a drop in blood cells causing an increase risk of infection.

The researchers found a drop in the women’s quality of life which they say couldn’t have happened by chance, that is to say it was statistically significant.  

The researchers concluded that the combination of docetaxel and gemcitabine had similar results to other chemotherapy treatments for women whose cervical cancer had come back. They suggest that future trials should look at combining chemotherapy with a biological therapy.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Paul Symonds

Supported by

Eli Lilly and Company Limited
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)
Sanofi
Scottish Gynaecological Cancer Trials Group

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 252

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page